PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis

Liu,Yuhong; Liu,Hui; Cao,Huiqin; Song,Bin; Zhang,Wen; Zhang,Wanggang

doi:10.3892/or.2015.4308

PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis

Authors:
- Yuhong Liu
- Hui Liu
- Huiqin Cao
- Bin Song
- Wen Zhang
- Wanggang Zhang
View Affiliations

Affiliations: Department of Hematology, The Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: September 24, 2015 https://doi.org/10.3892/or.2015.4308
Pages: 3288-3296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is a disorder involving hematopoietic stem cells, characterized by blockage of hematopoietic cell differentiation and an increase in clonal neoplastic proliferation. AML is associated with poor patient outcome. PBK/TOPK is a protein kinase derived from PDZ-binding kinase (PBK)/T-lymphokine-activated killer (T-LAK) cell-originated protein kinase (TOPK). Previous studies have shown that PBK/TOPK is expressed in hematologic tumors. In the present study, we aimed to investigate the role of PBK/TOPK in promyelocyte proliferation and to clarify the molecular mechanism. PBK/TOPK knockdown (KD) significantly decreased cell proliferation and viability in the NB4 and HL-60 promyelocytes. PBK/TOPK KD resulted in G2/M cell cycle arrest that attributed to a decrease in cdc2 and cyclin B expression. In addition, PBK/TOPK KD caused apoptosis, as evidenced by activation of the mitochondrial apoptotic pathway and an increase in TUNEL-positive cells. PBK/TOPK KD induced mitochondrial dysfunction and ROS generation, and inhibition of mitochondrial dysfunction and ROS production suppressed PBK/TOPK KD-induced cell cycle arrest and apoptosis. Moreover, PBK/TOPK KD decreased Nrf2 expression and ARE-binding activity. Overexpression of Nrf2 inhibited the PBK/TOPK KD-induced decrease in cdc2 and cyclin B expression and cell cycle arrest, and blocked ROS production and apoptosis. Based on literature and our results, it was demonstrated that Nrf2 may be a crucial regulator that mediates PBK/TOPK-exerted promotion of cell proliferation. PBK/TOPK stabilizes Nrf2, strictly regulates the ROS level, promotes cell cycle progression and inhibits apoptosis, contributing to the proliferation of promyelocytes. Our results provide new insights into the molecular mechanism of PBK/TOPK-mediated promyelocyte proliferation and shed light on the pathogenesis of AML.

View Figures

View References

1	Rampal R and Mascarenhas J: Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Curr Opin Hematol. 21:65–71. 2014. View Article : Google Scholar
2	Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC and de Thé H: Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 15:6321–6326. 2009. View Article : Google Scholar : PubMed/NCBI
3	Coombs CC, Tavakkoli M and Tallman MS: Acute promyelocytic leukemia: Where did we start, where are we now, and the future. Blood Cancer J. 5:e3042015. View Article : Google Scholar : PubMed/NCBI
4	Gaudet S, Branton D and Lue RA: Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci USA. 97:5167–5172. 2000. View Article : Google Scholar : PubMed/NCBI
5	Abe Y, Matsumoto S, Kito K and Ueda N: Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem. 275:21525–21531. 2000. View Article : Google Scholar : PubMed/NCBI
6	Zhao S, Dai J, Zhao W, Xia F, Zhou Z, Wang W, Gu S, Ying K, Xie Y and Mao Y: PDZ-binding kinase participates in spermatogenesis. Int J Biochem Cell Biol. 33:631–636. 2001. View Article : Google Scholar : PubMed/NCBI
7	Nandi A, Tidwell M, Karp J and Rapoport AP: Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol Dis. 32:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
8	Côté S, Simard C and Lemieux R: Regulation of growth-related genes by interleukin-6 in murine myeloma cells. Cytokine. 20:113–120. 2002. View Article : Google Scholar : PubMed/NCBI
9	Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D and Rapoport AP: PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis. 27:825–829. 2001. View Article : Google Scholar
10	Matsumoto S, Abe Y, Fujibuchi T, Takeuchi T, Kito K, Ueda N, Shigemoto K and Gyo K: Characterization of a MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun. 325:997–1004. 2004. View Article : Google Scholar : PubMed/NCBI
11	Ayllón V and O'connor R: PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene. 26:3451–3461. 2007. View Article : Google Scholar
12	Kumagai A and Dunphy WG: Control of the Cdc2/cyclin B complex in Xenopus egg extracts arrested at a G2/M checkpoint with DNA synthesis inhibitors. Mol Biol Cell. 6:199–213. 1995. View Article : Google Scholar : PubMed/NCBI
13	Clarke PR, Klebe C, Wittinghofer A and Karsenti E: Regulation of cdc2/cyclin b activation by ran, a ras-related GTPase. J Cell Sci. 108:1217–1225. 1995.PubMed/NCBI
14	Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al: Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. Apr 28–2015.Epub ahead of print. View Article : Google Scholar
15	Flusberg DA and Sorger PK: Surviving apoptosis: Life-death signaling in single cells. Trends Cell Biol. Apr 25–2015. View Article : Google Scholar : PubMed/NCBI
16	Sinha K, Das J, Pal PB and Sil PC: Oxidative stress: The mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 87:1157–1180. 2013. View Article : Google Scholar : PubMed/NCBI
17	Balaban RS, Nemoto S and Finkel T: Mitochondria, oxidants, and aging. Cell. 120:483–495. 2005. View Article : Google Scholar : PubMed/NCBI
18	Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol. 552:335–344. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bonora M and Pinton P: The mitochondrial permeability transition pore and cancer: Molecular mechanisms involved in cell death. Front Oncol. 4:3022014. View Article : Google Scholar : PubMed/NCBI
20	Chistiakov DA, Sobenin IA, Revin VV, Orekhov AN and Bobryshev YV: Mitochondrial aging and age-related dysfunction of mitochondria. Biomed Res Int. 2014:2384632014. View Article : Google Scholar : PubMed/NCBI
21	Correia-Melo C and Passos JF: Mitochondria: Are they causal players in cellular senescence? Biochim Biophys Acta. May 28–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
22	Singh KK: Mitochondria damage checkpoint, aging, and cancer. Ann NY Acad Sci. 1067:182–190. 2006. View Article : Google Scholar : PubMed/NCBI
23	Penna C, Perrelli MG and Pagliaro P: Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: Therapeutic implications. Antioxid Redox Signal. 18:556–599. 2013. View Article : Google Scholar
24	Osman MM, Lulic D, Glover L, Stahl CE, Lau T, van Loveren H and Borlongan CV: Cyclosporine-A as a neuroprotective agent against stroke: Its translation from laboratory research to clinical application. Neuropeptides. 45:359–368. 2011. View Article : Google Scholar : PubMed/NCBI
25	Rushworth GF and Megson IL: Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 141:150–159. 2014. View Article : Google Scholar
26	Kaspar JW, Niture SK and Jaiswal AK: Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 47:1304–1309. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hayes JD and McMahon M: NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
28	Zhang DD: Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev. 38:769–789. 2006. View Article : Google Scholar : PubMed/NCBI
29	DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI
30	Niture SK and Jaiswal AK: Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med. 57:119–131. 2013. View Article : Google Scholar : PubMed/NCBI
31	Burhans WC and Heintz NH: The cell cycle is a redox cycle: Linking phase-specific targets to cell fate. Free Radic Biol Med. 47:1282–1293. 2009. View Article : Google Scholar : PubMed/NCBI
32	Rushworth SA, MacEwan DJ and O'Connell MA: Lipo-polysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol. 181:6730–6737. 2008. View Article : Google Scholar : PubMed/NCBI
33	Rushworth SA, Bowles KM and MacEwan DJ: High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res. 71:1999–2009. 2011. View Article : Google Scholar : PubMed/NCBI